Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [177Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer. — SciRadar